Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Jul 16.
Published in final edited form as: J Mol Cell Cardiol. 2001 Apr;33(4):825–830. doi: 10.1006/jmcc.2001.1338

Targeted Deletion of the A3 Adenosine Receptor Confers Resistance to Myocardial Ischemic Injury and does not Prevent Early Preconditioning

Yiru Guo 1, Roberto Bolli 1, Weike Bao 1, Wen-Jian Wu 1, Richard G Black Jr 1, Sidney S Murphree 2, Christopher A Salvatore 3, Marlene A Jacobson 3, John A Auchampach 1
PMCID: PMC4100593  NIHMSID: NIHMS477767  PMID: 11273734

Abstract

We used mice with genetic disruption of the A3 adenosine receptor (AR) gene (A3AR−/− mice) to assess the in vivo role of the A3AR in modulating myocardial ischemia/reperfusion injury and preconditioning (PC). Surprisingly, infarct size induced by 30 min of coronary artery occlusion and 24 h of reperfusion was 35% smaller in A3AR−/− compared to wild-type mice (A3AR+/+). The reduction in infarct size was not the result of differences in heart rate, body temperature or increased cardiac expression of A1ARs. However, neutrophil infiltration within infarcted regions was less in A3AR−/− mice. Furthermore, ischemic PC induced by either a single episode (one 5 min occlusion) or multiple episodes (six 4 min occlusions) of ischemia produced equivalent reductions in infarct size in A3AR−/− and A3AR+/+ mice. These results indicate that, in the mouse, (i) A3ARs play an injurious role during acute myocardial ischemia/reperfusion injury, possibly by exacerbating the inflammatory response, and (ii) A3ARs are not necessary for the development of the early phase of ischemic PC.

Keywords: Adenosine receptor, Ischemia/reperfusion, Preconditioning, Heart, Knock-out mice

Introduction

Recent evidence suggests that pharmacological activation of A3 adenosine receptors (ARs) prior to an ischemic challenge can induce both early and late preconditioning (PC).15 However, the functional importance of the A3AR in modulating injury during acute myocardial ischemia remains to be determined. Furthermore, it is unclear whether or not ischemia-induced PC is mediated through the A3AR.1,3,68 To address these issues, highly selective A3AR antagonists are required, which are not currently available. Recently, however, genetically engineered mice have been created in which the A3AR gene is selectively disrupted.9,10 In this study, we used A3AR−/− mice to examine the role of the A3AR in the genesis of ischemia/reperfusion injury and ischemic PC using a physiologically-relevant in vivo mouse model of infarction.11 Our results suggest that A3ARs play an injurious role during acute myocardial infarction and that they are not essential for the development of ischemia-induced early PC.

Materials and Methods

In vivo mouse model

Studies were performed in A3AR+/+ and A3AR−/− (Sv129/C57B/6/D2) male mice weighing 26–35 g (10–14 weeks old). The open-chest mouse model of regional ischemia and reperfusion has been previously described in detail.11 At the end of the experiments, infarct size was assessed by ex vivo staining with triphenyltetrazolium chloride and expressed as a percentage of the area at risk.11 Ischemic PC was elicited by either a single 5 min occlusion/10 min reperfusion cycle (single cycle PC) or a sequence of six 4 min occlusion/4 min reperfusion cycles (multiple cycle PC).

Six groups of mice were studied (Fig. 1). Groups I (A3AR+/+) and II (A3AR−/−) served as control groups and were subjected to 30 min occlusion and 24 h reperfusion without PC. Groups III (A3AR+/+) and IV (A3AR−/−) underwent the single cycle PC protocol immediately before a 30 min period of occlusion and 24 h of reperfusion. Finally, groups V (A3AR+/+) and VI (A3AR−/−) underwent the multiple cycle PC protocol immediately before a 30 min period of occlusion and 24 h of reperfusion.

Figure 1.

Figure 1

(A) Experimental protocol. (B) Myocardial infarct size in groups I–VI. Infarct size is expressed as a percentage or the area at risk of infarction. Individual mice (○); mean±s.e.m. for respective groups (●).

Neutrophil accumulation

A3AR+/+ mice (n = 6) or A3AR−/− mice (n = 6) were subjected to 30 min of coronary artery occlusion and 3 h of reperfusion, after which the hearts were fixed in paraformaldehyde, sectioned and then stained with hematoxylin and eosin. The average number of neutrophils per high power field in midmyocardial zones that showed clear evidence of infarction was counted in three independent fields.

Radioligand binding

A1AR density in heart membranes from A3AR+/+ and A3AR−/− mice was determined by quantification of specific binding of the A1AR-antagonist 8-cyclopentyl-1,3-[3H]dipropylxanthine ([3H]CPX).

Statistical analysis

Data are reported as means±s.e.m.. Heart rate and body temperature were analysed by two-way repeated measures ANOVA (time and group). Infarct size, risk region size and accumulation of neutrophils were analysed with one-way ANOVA followed by unpaired t-tests with Bonferroni’s correction.

Results

Exclusions

A total of 67 mice (33 A3AR+/+ and 34 A3AR−/− mice) were used in the studies. Seven mice died in the A3AR+/+ group and eight died in the A3AR−/− group.

Heart rate and body temperature

There were no significant differences among the different treatment groups in either of these two determinants of infarct size at any time throughout the experiments (Table 1).

Table 1.

Body temperature and heart rate during 30 min coronary occlusion and following reperfusion

Preocclusion Occlusion 15′ Occlusion 30′ Reperfusion 5′ Reperfusion 15′
Temperature (°C)
Group I 37.0 ± 0.1 37.0 ± 0.1 37.1 ± 0.1 37.0 ± 0.0 37.1 ± 0.1
Group II 37.0 ± 0.1 37.1 ± 0.0 37.1 ± 0.1 37.0 ± 0.1 37.0 ± 0.1
Group III 37.1 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 36.9 ± 0.0 36.8 ± 0.1
Group IV 37.0 ± 0.1 37.0 ± 0.0 37.1 ± 0.1 36.9 ± 0.0 36.9 ± 0.1
Group V 37.1 ± 0.1 37.0 ± 0.1 37.1 ± 0.0 37.1 ± 0.1 37.0 ± 0.1
Group VI 36.9 ± 0.1 37.1 ± 0.1 36.9 ± 0.1 37.0 ± 0.1 36.9 ± 0.1
Heart rate (beats/min)
Group I 490 ± 14 525 ± 14 520 ± 12 559 ± 13 550 ± 15
Group II 525 ± 13 549 ± 19 559 ± 18 577 ± 19 578 ± 20
Group III 520 ± 19 535 ± 17 549 ± 20 547 ± 25 543 ± 30
Group IV 534 ± 11 545 ± 14 562 ± 17 563 ± 13 570 ± 19
Group V 505 ± 16 511 ± 15 516 ± 11 527 ± 8 536 ± 13
Group VI 543 ± 14 553 ± 12 559 ± 14 573 ± 8 571 ± 11

Data are means ± s.e.m. Measurements of rectal temperature and heart rate were taken before the 30 min coronary occlusion (preocclusion), at 15 and 30 min into the 30 min occlusion, and 5 and 15 min after reperfusion. The experimental protocols for the six mouse groups are specified in the legend to Figure 1.

Myocardial infarct size

There were no significant differences among the six groups with respect to body weight, left ventricular weight or weight of the region at risk (Table 2). In group I (A3AR+/+ mice), infarct size averaged 57.0±2.9% of the area at risk (Fig. 1 and Table 2). In contrast, infarct size in group II (A3AR−/−) was only 36.0±4.0% of the region at risk (P<0.05 v group I; Fig. 1 and Table 2), indicating that the extent of cell death was reduced by ~35% in mice lacking functional A3ARs.

Table 2.

Size of left ventricle, risk region and infarct

Age
(week)
Body
(g)
LV
(mg)
Risk region
(mg)
Infarct
(mg)
Risk region
(% or LV)
Infarct (% of
risk region)
Infarct
(% of LV)
Group I 14.3 ± 1.9 32.1 ± 1.2 121.6 ± 5.2 44.0 ± 3.0 25.2 ± 2.2 34.0 ± 1.9 57.0 ± 2.9 19.3 ± 1.4
Group II 14 3 ± 0.6 30.3 ± 1.3 116.9 ± 5.1 42.4 ± 3.8 14.6 ± 1.5* 36.0 ± 2.1 36.0 ± 4.0* 12.5 ± 1.3*
Group III 11.5 ± 0.8 27.6 ± 0.8 103.8 ± 8.2 38.8 ± 3.3 11.5 ± 1.7*# 37.9 ± 2.6 21.4 ± 5.2*# 7.6 ± 1.5*#
Group IV 12.0 ± 0.7 28.9 ± 0.5 104.1 ± 5.4 39.7 ± 2.8 4.7 ± 1.2*# 38.2 ± 1.8 11.2 ± 2.5*# 4.4 ± 1.0*#
Group V 10.3 ± 0.8 28.0 ± 1.1 118.3 ± 8.2 35.4 ± 1.9 6.4 ± 1.3*# 30.5 ± 2.3 17.5 ± 3.0*# 5.6 ± 1.1*#
Group VI 10.6 ± 0.8 26.5 ± 0.7 110.6 ± 8.3 37.7 ± 3.4 5.2 ± 1.8*# 34.1 ± 2.2 9.6 ± 3.5*# 3.5 ± 1.5*#

LV, left ventricle; Body, body weight. Data are means ± s.e.m.

*

P<0.05 v group I,

#

P<0.05 v group II.

In groups III and V (A3AR+/+ mice), PC with either one or six occlusion/reperfusion cycles reduced infarct size to 21.4±5.2 and 17.5±3.0% of the region at risk, respectively (P<0.05 v group I; Fig. 1 and Table 2). A similar PC effect was noted in groups IV and VI (A3AR−/− mice), in which infarct size was 11.2±2.5% and 9.6±3.5%, respectively.

Neutrophil accumulation

The number of neutrophils that accumulated within infarcted regions following 30 min of occlusion and 3 h of reperfusion was significantly less (P<0.05) in A3AR−/− mice compared to A3AR+/+ mice (5.1±0.4 v 3.0±0.7 neutrophils per high power field, respectively; n = 6/group).

Radioligand binding

Radioligand binding data revealed that the level of expression of A1ARs was equivalent in membranes prepared from the left ventricles of A3AR+/+ and A3AR−/− mice. The calculated Kd and Bmax values were 0.7±0.3 nm and 5±2 fmol/mg protein, respectively (n = 3), for A3AR+/+ mice, and 0.8±0.3 nm and 6±2 fmol/mg protein, respectively (n = 3), for A3AR−/− mice.

Discussion

Recent evidence suggests that A3ARs are expressed in the heart and that pretreatment with A3AR agonists induces both the early and late phases of PC.15 To date, however, it has not been possible to assess the role of the A3AR during acute myocardial ischemia (as opposed to their role in triggering PC), due to the unavailability of selective A3AR antagonists. Thus, we used a molecular genetic approach and examined A3AR−/− mice. We made the surprising observation that infarct size induced by 30 min of coronary occlusion and 24 h of reperfusion is smaller in A3AR−/− compared to A3AR+/+ mice, suggesting that mice lacking functional A3ARs are more resistant to the development of irreversible ischemic injury. To the best of our knowledge, this is the first study to assess infarct size in A3AR−/− mice in vivo. Our results support the novel concept that some of the actions of adenosine mediated through the A3AR are detrimental to the ischemic myocardium.

The mechanisms by which the A3AR may exacerbate ischemic injury remain to be ascertained. A3ARs are expressed in resident inflammatory cells such as mast cells9,10 where they can stimulate the release of stored mediators including histamine, cytokines, proteolytic enzymes as well as numerous other pro-inflammatory mediators. Adenosine-induced activation of mast cells has been shown to be responsible for increased vascular permeability and extravasation of serum proteins in mice.10 Accordingly, it is possible that A3ARs may increase infarct size by potentiating the inflammatory response. In support of this hypothesis, we observed that the number of neutrophils within infarcted regions in A3AR+/+ mice was significantly greater than in A3AR−/− mice. It is impossible to discriminate, however, whether the reduced neutrophil accumulation in A3AR−/− mice was the cause or the result of smaller infarcts. Since A3ARs have also been suggested to induce apoptosis in cardiomyocytes12 and to negatively regulate vascular tone,13 other potential mechanisms by which A3ARs may promote the development of ischemic injury include promoting apoptosis or decreasing coronary blood flow. The possibility that the reduction in infarct size in A3AR−/− mice was due to differences in systemic hemodynamics or body temperature can be ruled out, since these variables were similar throughout the studies (Table 1) and since it has been demonstrated previously that systemic blood pressure is not altered in A3AR−/− mice.13 It must be kept in mind, however, that the reduction in infarct size in A3AR−/− mice may be the result of compensatory changes which occur due to chronic absence of A3ARs. Our radioligand binding studies exclude the possibility that expression levels of A1ARs are altered in A3AR−/− mice. Additional studies with A3AR-selective antagonists, once developed, will be necessary to test whether acute blockade of A3ARs influences the development of ischemic injury.

Another important finding of the present study is that the early phase of ischemic PC is fully manifest in A3AR−/− mice. These results provide conclusive evidence that the A3AR is not necessary for the development of the early phase of ischemic PC. Previously, the role of the A3AR as a mediator of ischemic PC has been the subject of debate. In isolated rabbit and mouse hearts, Hill and colleagues7 and Morrison and colleagues8 demonstrated that blockade of A1ARs abolishes ischemic PC, suggesting that this receptor subtype is the sole mediator of PC. However, Liu and coworkers3 observed in isolated rabbit hearts that the protection induced by ischemia, adenosine, and N6-(3-aminophenylethyl)adenosine (APNEA: A1/A3AR agonist) could not be blocked by CPX, suggesting that the protection of PC is not mediated exclusively by the A1AR and may involve the A3AR. Finally, Armstrong and Ganote1,6 proposed that the A3AR is the sole mediator of PC in isolated rabbit cardiomyocytes, based on the observation that CPX does not block ischemia-induced PC and that the A1AR-selective agonist (R)-N6-phenylisopropyladenosine (R-PIA) is incapable of inducing PC at lower concentrations in this model system. It is likely that these discrepant observations are the result of species differences, differences in the model systems employed, as well as the use of non-selective ligands. Our findings in A3AR−/− mice are consistent with the hypothesis that either the A1AR is the sole mediator of PC or that both A1 and A3ARs can mediate PC.

In summary, the present study demonstrates that infarct size is smaller in A3AR−/− mice, suggesting that A3ARs play an injurious role during myocardial ischemia. Our results further demonstrate that the A3AR is not essential for the development of the early phase of ischemic PC. Both of these findings have important implications for our understanding of the function or these receptors in modulating ischemia/reperfusion injury in the heart.

Acknowledgements

This study was supported in part by NIH grants R01 HL-60051 (JAA), HL-43151 (RB) and HL-55757 (RB); National AHA Grant 9630083N (JAA); American Heart Association Ohio Valley Affiliate Grants KY-9804557 and 9920595 (YG); and the Medical Research Grant Program of the Jewish Hospital Foundation, Louisville, KY.

References

  • 1.Armstrong S, Ganote CE. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: evidence of A3 receptor involvement. Cardiovasc Res. 1994;28:1049–1056. doi: 10.1093/cvr/28.7.1049. [DOI] [PubMed] [Google Scholar]
  • 2.Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, Bolli R. Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res. 1997;80:800–809. doi: 10.1161/01.res.80.6.800. [DOI] [PubMed] [Google Scholar]
  • 3.Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res. 1994;28:1057–1061. doi: 10.1093/cvr/28.7.1057. [DOI] [PubMed] [Google Scholar]
  • 4.Strickler J, Jacobson KA, Liang BT. Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest. 1996;98:1773–1779. doi: 10.1172/JCI118976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Takano H, Bolli R, Black RG, Jr, Kodani E, Yang Z, Tang XL, Bhattacharya S, Auchampach JA. Activation of A1 or A3 adenosine receptors induces late preconditioning against infarction in conscious rabbits by different mechanisms. Circulation Research. 2000;32 doi: 10.1161/01.res.88.5.520. A54 (Abstract). [DOI] [PubMed] [Google Scholar]
  • 6.Armstrong S, Ganote CE. In vitro ischaemic preconditioning of isolated rabbit cardiomyocytes: effects of selective adenosine receptor blockade and calphostin C. Cardiovasc Res. 29:647–652. [PubMed] [Google Scholar]
  • 7.Hill RJ, Oleynek JJ, Magee W, Knight DR, Tracey WR. Relative importance of adenosine A1 and A3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J Mol Cell Cardiol. 1998;30:579–585. doi: 10.1006/jmcc.1997.0621. [DOI] [PubMed] [Google Scholar]
  • 8.Morrison RR, Jones R, Byford AM, Stell AR, Peart J, Headrick JP, Matherne GP. Transgenic overexpression of cardiac A1 adenosine receptors mimics ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2000;279:H1071–H1078. doi: 10.1152/ajpheart.2000.279.3.H1071. [DOI] [PubMed] [Google Scholar]
  • 9.Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem. 2000;275:4429–4434. doi: 10.1074/jbc.275.6.4429. [DOI] [PubMed] [Google Scholar]
  • 10.Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, Koller BH. Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells. J Clin Invest. 2000;105:361–367. doi: 10.1172/JCI8253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol. 1998;275:H1375–H1387. doi: 10.1152/ajpheart.1998.275.4.H1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Shneyvays V, Jacobson KA, Li AH, Nawrath H, Zinman T, Isaac A, Shainberg A. Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res. 2000;257:111–126. doi: 10.1006/excr.2000.4882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhao Z, Makaritsis K, Francis CE, Gavras H, Ravid K. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta. 2000;1500:280–290. doi: 10.1016/s0925-4439(99)00111-8. [DOI] [PubMed] [Google Scholar]

RESOURCES